{"id":9949,"date":"2025-10-07T09:50:28","date_gmt":"2025-10-07T04:20:28","guid":{"rendered":"https:\/\/tradesmartonline.in\/blog\/?p=9949"},"modified":"2025-10-07T09:50:28","modified_gmt":"2025-10-07T04:20:28","slug":"rubicon-research-ipo-gmp","status":"publish","type":"post","link":"https:\/\/designingprojectmanagement.com\/blog\/rubicon-research-ipo-gmp\/","title":{"rendered":"Rubicon Research IPO GMP, Price, Lot Size, & Allotment Details"},"content":{"rendered":"

Rubicon Research IPO \u2013 An Overview and Company Insight<\/strong><\/span><\/h2>\n

Rubicon Research IPO GMP is drawing early attention from the investor community, especially in the pharma \/ specialty formulations space. Rubicon Research is a specialty pharmaceutical company that develops, manufactures, and markets differentiated formulations and drug-device combinations, particularly targeting regulated markets like the U.S. The company has R&D centers in India and Canada, and multiple manufacturing sites in India. They hold US FDA and WHO-GMP accreditations, giving them credibility in international markets.
The IPO is a mix of fresh issue + Offer For Sale (OFS). The fresh portion is aimed at reducing debt, supporting inorganic growth, and funding strategic investments. The OFS gives promoters \/ early investors a chance to exit partially. With performance improving in recent years, Rubicon is positioning itself as a growth story in Indian pharma.<\/p>\n

Rubicon Research IPO \u2013 Grey Market Premium (GMP)<\/strong><\/span><\/h2>\n

At this stage, a well-confirmed GMP for Rubicon Research hasn\u2019t been firmly established. Market whispers suggest modest premiums depending on subscription interest. Because there\u2019s a significant OFS portion, investor sentiment will likely be tempered. If demand is strong, a listing gain of 5-10% over the upper price band<\/strong> could be possible. Investors will be closely watching anchor allocations, subscription trends, and how the GMP evolves closer to listing.<\/p>\n

Rubicon Research IPO GMP<\/strong><\/span><\/h2>\n
\n\n\n\n\n\n
Date<\/strong><\/td>\nIPO GMP<\/strong><\/td>\nGMP Trend<\/strong><\/td>\nGain<\/strong><\/td>\n<\/tr>\n
Today<\/td>\n\u20b980<\/td>\n\"IPO<\/td>\n16.49%<\/td>\n<\/tr>\n
6 Oct<\/td>\n\u20b968<\/td>\n\"IPO<\/td>\n14.02%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n
<\/div>\n

Pricing Details and Lot Size \u2013 Rubicon Research IPO<\/strong><\/span><\/h3>\n